Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension

Annals of the American Thoracic Society

Volumn 12, Issue 3, 2015, Pages 370-375

  Matura, Lea Ann ^a   Ventetuolo, Corey E ^b   Palevsky, Harold I ^c   Lederer, David J ^d   Horn, Evelyn M ^d   Mathai, Stephen C ^e   Pinder, Diane ^c   Archer Chicko, Christine ^c   Bagiella, Emilia ^f   Roberts, Kari E ^g   Tracy, Russell P ^h   Hassoun, Paul M ^e   Girgis, Reda E ⁱ   Kawut, Steven M ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d College of Physicians and Surgeons ^*  (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ SPECTRUM HEALTH   (United States)

Author keywords

Fatigue; Interleukin 6; Pain; Pulmonary arterial hypertension; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; BOSENTAN; ILOPROST; INTERLEUKIN 6; PROSTACYCLIN; SILDENAFIL; SIMVASTATIN; TREPROSTINIL; TUMOR NECROSIS FACTOR ALPHA; WARFARIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IL6 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; PAIN; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SYMPTOM ASSESSMENT; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ASPIRIN; BIOMARKERS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; QUALITY OF LIFE; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961287741     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201410-463OC     Document Type: Article

References (53)

1. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376.387.
2. Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, Li J, Gao I, Qu JM, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:303.310.
3. Galiè N, Hoeper MM, Humbert M, Torbicki A, Bachiery JL, Barbera JA, Beghhetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493.2537.
4. Matura L, McDonough A, Carroll D. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs 2012;11:51.61.
5. Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs 2014;29:178.184.
6. McDonough A, Matura L, Carroll D. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res 2011;20:120.134.
7. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013;144:160.168.
8. McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, Yaeger T, Weintraub P, Badesch DB. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 2010;51:339.339. e8.
9. Lowe B, Grafe K, Ufer C, Kroenke K, Grúnig E, Herzog W, Borst MM. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004;66:831.836.
10. Dantzer R, Bluthé RM, Layé S, Bret-Dibat J-L, Parnet P, Kelley KW. Cytokines and sickness behavior. Ann N Y Acad Sci 1998;840:586.590.
11. Miller AH. Norman Cousins Lecture: Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009;23:149.158.
12. Heffner KL, France CR, Trost Z, Ng HM, Pigeon WR. Chronic low back pain, sleep disturbance, and interleukin-6. Clin J Pain 2011;27:35.41.
13. Poleshuck EL, Talbot NL, Moynihan JA, Chapman BP, Heffner KL. Depressive symptoms, pain, chronic medical morbidity, and interleukin-6 among primary care patients. Pain Med 2013;14:686.691.
14. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of proinflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995;63:289.302.
15. Graham JE, Robles TF, Kiecolt-Glaser JK, Malarkey WB, Bissell MG, Glaser R. Hostility and pain are related to inflammation in older adults. Brain Behav Immun 2006;20:389.400.
16. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24.31.
17. Parissis JT, Adamopoulos S, Rigas A, Kostakis G, Karatzas D, Venetsanou K, Kremastinos DT. Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004;94:1326.1328.
18. Vogelzangs N, Beekman ATF, De Jonge P, Penninx BWJH. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry 2013;3:e249.
19. Brouwers C, Mommersteeg PMC, Nykļček I, Pelle AJ, Westerhuis BL, Szabó BM, Denollet J. Positive affect dimensions and their association with inflammatory biomarkers in patients with chronic heart failure. Biol Psychol 2013;92:220.226.
20. Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, Lúftner D. Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat 2012;136:789.794.
21. Dorfmúller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358.363.
22. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920.927.
23. Deshpande P, Rajan S, Sudeepthi B, Abdul Nazir C. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res 2011;2:137.144.
24. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension/clinical perspective. Circulation 2011;123:2985.2993.
25. Matura L, Palevsky H, Lederer D, Horn EM, Pinder D, Archer-Chicko C, Roberts KE, Tracy RP, Girgis RE, Hassound PM, et al. Plasma interleukin-6 is associated with symptoms in pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2013;187:A4012.
26. Kawut SM, Bagiella E, Shimbo D, Lederer DJ, Al-Naamani N, Roberts KE, Barr RG, Post W, Horn EM, Tracy R, et al.; ASA-STAT Study Group. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemp Clin Trials 2011;32:280.287.
27. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 Health Survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160.164.
28. Achat H, Kawachi I, Spiro A, Dem Olles DA, Sparrow D. Optimism and depression as predictors of physical and mental health functioning: The Normative Aging Study. Ann Behav Med 2000;22:127.130.
29. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36). I. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247.263.
30. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA Study. Atherosclerosis 2005;183:308-315.
31. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-798.
32. SAS Institute Inc. SAS 9.1.3. Cary, NC: SAS Institute Inc.; 2000-2004.
33. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 2008;22:24-32.
34. Cho HJ, Kivimäki M, Bower JE, Irwin MR. Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study. Psychol Med 2013;43:1773-1783.
35. Lasselin J, Layé S, Dexpert S, Aubert A, Gonzalez C, Gin H, Capuron L. Fatigue symptoms relate to systemic inflammation in patients with type 2 diabetes. Brain Behav Immun 2012;26:1211-1219.
36. Fink AM, Gonzalez RC, Lisowski T, Pini M, Fantuzzi G, Levy WC, Piano MR. Fatigue, inflammation, and projected mortality in heart failure. J Card Fail 2012;18:711-716.
37. O'Donovan A, Hughes BM, Slavich GM, Lynch L, Cronin MT, O'Farrelly C, Malone KM. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 2010;24:1074-1077.
38. Jehn C, Kühnhardt D, Possinger K, Flath B. Plasma IL-6 and HPA-axis function in depression and anxiety in patients with cancer. J Clin Oncol (Meeting Abstracts) 2005;23(Suppl 16):8033.
39. Bob P, Raboch J, Maes M, Susta M, Pavlat J, Jasova D, Vevera J, Uhrova J, Benakova H, Zima T. Depression, traumatic stress and interleukin-6. J Affect Disord 2010;120:231-234.
40. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun 2011;25:1725-1734.
41. Alstergren P, Kopp S. Insufficient endogenous control of tumor necrosis factor-a contributes to temporomandibular joint pain and tissue destruction in rheumatoid arthritis. J Rheumatol 2006;33:1734-1739.
42. Ter Wolbeek M, Van Doornen LJP, Kavelaars A, Tersteeg-Kamperman MDJ, Heijnen CJ. Fatigue, depressive symptoms, and anxiety from adolescence up to young adulthood: a longitudinal study. Brain Behav Immun 2011;25:1249-1255.
43. Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D. Serum concentrations of CRP, IL-6, TNF-a and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 2012;198:74-80.
44. Blackmore ER, Moynihan JA, Rubinow DR, Pressman EK, Gilchrist M, O'Connor TG. Psychiatric symptoms and proinflammatory cytokines in pregnancy. Psychosom Med 2011;73:656-663.
45. Kwak SM, Choi YS, Yoon HM, Kim DG, Song SH, Lee YJ, Yeom CH, Koh SJ, Park J, Lee MA, et al. The relationship between interleukin-6, tumor necrosis factor-a, and fatigue in terminally ill cancer patients. Palliat Med 2012;26:275-282.
46. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007;21:413-427.
47. Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M. Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol 2011;24:261-264.
48. Bien S, Riad A, Ritter CA, Gratz M, Oishausen G, Wetermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 2007;67:10428-10435.
49. Wahlström MR, Olivecrona M, Ahlm C, Bengstsson A, Koskinen LO, Naredi S, Hultin M. Effects of prostacyclin on the early inflammatory response in patients with traumatic brain injury: a randomised clinical study. Springerplus 2014;3:98.
50. Eisenhut T, Sinha B, Gröttrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-a in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993;26:259-264.
51. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008;25:37-44.
52. Smart NA, Larsen AI, Le Maitre JP, Ferraz AS. Effect of exercise training on interleukin-6, tumour necrosis factor a and functional capacity in heart failure. Cardiol Res Pract 2011;2011:532620.
53. Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008;27:124-130.